12:00 AM
 | 
May 20, 2002
 |  BioCentury  |  Tools & Techniques

Sopping up SAP

Researchers finally may have found a way to attack the amyloid deposits associated with Alzheimer's disease and other disorders. In last week's Nature, researchers published their efforts to develop therapeutics to treat amyloidosis, showing that their compound, CPHPC, depleted serum amyloid P component (SAP) (APCS) from both the blood and tissues of patients.

Due to its unique mechanism of action, CPHPC potentially could be used to treat both Type II diabetes and Alzheimer's (AD), which are associated with amyloid deposits in the islet cells and brain, respectively.

Though normally soluble, SAP binds to amyloid fibrils and is always associated with amyloid deposits. SAP binding to fibrils renders the deposits resistant to proteolytic enzymes and phagocytic cells, leading researchers to hypothesize that reducing SAP levels could reduce the severity...

Read the full 622 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >